



PTO/SB/08A (08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Project of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete If Known

| | |
|------------------------|-------------------|
| Application Number | 10/565,741 |
| Filing Date | January 23, 2006 |
| First Named Inventor | Yolande Chvatchko |
| Art Unit | 1644 |
| Examiner Name | |
| Attorney Docket Number | ARS-120 |

Sheet

1

of

6

U.S. PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|-----------------------|--------------------------|-----------------------------------------------|--------------------------------|----------------------------------------------------|---------------------------------------------------------------------------------|
| | | Number - Kind Code ² (if known) | | | |
| | U1 | US- | | | |
| | U2 | US- | | | |
| | U3 | US- | | | |
| | U4 | US- | | | |
| | U5 | US- | | | |
| | U6 | US- | | | |
| | U7 | US- | | | |
| | U8 | US- | | | |
| | U9 | US- | | | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁴ |
|-----------------------|--------------------------|-------------------------------------------------------------------------------------|--------------------------------|----------------------------------------------------|---------------------------------------------------------------------------------|----------------|
| | | Country Code ³ - Number ⁴ - Kind Code ⁵ (if known) | | | | |
| /MH/ | F1 | WO 02/098917 A2 (CD-ROM) | 12-12-2002 | Curagen Corporation | All | |
| /MH/ | F2 | EP 1033401 A2 (CD-ROM) | 09-06-2000 | Genset | All | |
| | F3 | | | | | |
| | F4 | | | | | |
| | F5 | | | | | |
| | F6 | | | | | |
| | F7 | | | | | |

Examiner
Signature

/Maher Haddad/

Date
Considered

10/11/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--------------------------------------------------------------------------------------------------------------------------------|---|--------------------------|-------------------|------------------------|---------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Complete if Known | | | |
| | | Application Number | 10/565,741 | | |
| | | Filing Date | January 23, 2006 | | |
| | | First Named Inventor | Yolande Chvatchko | | |
| | | Group Art Unit | 1644 | | |
| | | Examiner Name | | | |
| Sheet | 2 | of | 6 | Attorney Docket Number | ARS-120 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| /MH/ | R1 | ALTSCHUL, S.F. <i>et al.</i> "Basic Local Alignment Search Tool," <i>J. Mol. Biol.</i> , 1990, pp. 403-410, Vol. 215. | |
| | R2 | ALTSCHUL, S.F. <i>et al.</i> "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs," <i>Nucleic Acids Research</i> , 1997, pp. 3389-3402, Vol. 25, No. 17. | |
| | R3 | ANTHONY-CAHILL, S.J. and MAGLIERY, T.J. "Expanding the Natural Repertoire of Protein Structure and Function," <i>Current Pharmaceutical Biotechnology</i> , 2002, pp. 299-315, Vol. 3. | |
| | R4 | ARMALEO, D. <i>et al.</i> "Biostatic nuclear transformation of <i>Saccharomyces cerevisiae</i> and other fungi," <i>Curr Genet</i> , 1990, pp. 97-103, Vol. 17. | |
| | R5 | BROWN, A.R. <i>et al.</i> "The Total Chemical Synthesis of Monocyte Chemotactic Protein-1 (MCP-1)," <i>Journal of Peptide Science</i> , 1996, pp. 40-46, Vol. 2. | |
| | R6 | BRUTLAG, D.L. <i>et al.</i> "Improved sensitivity of biological sequence database searches," <i>Comput Appl Biosci</i> , 1990, pp. 237-245, Vol. 6, No. 3. | |
| | R7 | CASI, G. and HILVERT, D. "Convergent protein synthesis," <i>Current Opinion in Structural Biology</i> , 2003, pp. 589-594, Vol. 13. | |
| | R8 | CHAI, H. <i>et al.</i> "Glycosylation and high-level secretion of human tumour necrosis factor- β in recombinant baculovirus-infected insect cells," <i>Biotechnol. Appl. Biochem.</i> , 1993, pp. 259-273, Vol. 18. | |
| | R9 | CHAN, J.Y.-H. <i>et al.</i> "Relationship between Novel Isoforms, Functionally Important Domains, and Subcellular Distribution of CD164/Endolyn," <i>The Journal of Biological Chemistry</i> , January 19, 2001, pp. 2139-2152, Vol. 276, No. 3. | |
| | R10 | CLARK, A.J. "The Mammary Gland as a Bioreactor: Expression, Processing, and Production of Recombinant Proteins," <i>Journal of Mammary Gland Biology and Neoplasia</i> , 1998, pp. 337-350, Vol. 3, No. 3. | |
| | R11 | CLELAND, J.L. "The Development of Stable Protein Formulations: A Close Look at Protein Aggregation, Deamidation, and Oxidation," <i>Critical Reviews in Therapeutic Drug Carrier Systems</i> , 1993, pp. 307-377, Vol. 10, No. 4. | |
| ✓ | R12 | CLELAND, J.L. "Emerging protein delivery methods," <i>Current Opinion in Biotechnology</i> , 2001, pp. 212-219, Vol. 12. | |
| /MH/ | R13 | CUNNINGHAM, B.C. and WELLS, J.A. "High-Resolution Epitope Mapping of hGH-Receptor Interactions by Alanine-Scanning Mutagenesis," <i>Science</i> , June 2, 1989, pp. 1081-1085, Vol. 244. | |

| | | | |
|--------------------|----------------|-----------------|------------|
| Examiner Signature | /Maher Haddad/ | Date Considered | 10/11/2007 |
|--------------------|----------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98: The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--------------------------------------------------------------------------------------------------------------------------------|---|--------------------------|-------------------|------------------------|---------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Complete if Known | | | |
| | | Application Number | 10/565,741 | | |
| | | Filing Date | January 23, 2006 | | |
| | | First Named Inventor | Yolande Chvatchko | | |
| | | Group Art Unit | 1644 | | |
| | | Examiner Name | | | |
| Sheet | 3 | of | 6 | Attorney Docket Number | ARS-120 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| /MH/ | R14 | DOUGHERTY, D.A. "Unnatural amino acids as probes of protein structure and function," <i>Current Opinion in Chemical Biology</i> , 2000, pp. 645-652, Vol. 4. | |
| | R15 | DOYONNAS, R. <i>et al.</i> "CD164 Monoclonal Antibodies That Block Hemopoietic Progenitor Cell Adhesion and Proliferation Interact with the First Mucin Domain of the CD164 Receptor," <i>The Journal of Immunology</i> , 2000, pp. 840-851, Vol. 165. | |
| | R16 | FELDMAN, L.J. "Adenovirus-mediated arterial gene therapy for restenosis: problems and perspectives," <i>Semin Intervent Cardiol</i> , 1996, pp. 203-208, Vol. 1. | |
| | R17 | GENDEL, S.M. "Sequence Analysis for Assessing Potential Allergenicity," <i>Annals New York Academy of Sciences</i> , 2002, pp. 87-98, Vol. 964. | |
| | R18 | GENTZ, R. <i>et al.</i> "Bioassay for trans-activation using purified human immunodeficiency virus <i>tat</i> -encoded protein: Trans-activation requires mRNA synthesis," <i>Proc. Natl. Acad. Sci. USA</i> , February 1989, pp. 821-824, Vol. 86. | |
| | R19 | GISH, W. and STATES, D.J. "Identification of protein coding regions by database similarity search," <i>Nature Genetics</i> , March 1993, pp. 266-272, Vol. 3. | |
| | R20 | GOLEBIOWSKI, A. <i>et al.</i> "High-throughput organic synthesis of peptide mimetics," <i>Current Opinion in Drug Discovery and Development</i> , 2001, pp. 428-434, Vol. 4, No. 4. | |
| | R21 | GONNET, G.H. <i>et al.</i> "Exhaustive Matching of the Entire Protein Sequence Database," <i>Science</i> , June 5, 1992, pp. 1443-1445, Vol. 256. | |
| | R22 | GOR, D.O. <i>et al.</i> "T _H 1-T _H 2: a Procrustean paradigm," <i>Nature Immunology</i> , June 2003, pp. 503-505, Vol. 4, No. 6. | |
| | R23 | GRADDIS, T.J. <i>et al.</i> "Designing Proteins That Work Using Recombinant Technologies," <i>Current Pharmaceutical Biotechnology</i> , 2002, pp. 285-297, Vol. 3. | |
| | R24 | GUSTAFSSON, C. <i>et al.</i> "Codon bias and heterologous protein expression," <i>TRENDS in Biotechnology</i> , July 2004, pp. 346-353, Vol. 22, No. 7. | |
| ✓ | R25 | HENIKOFF, S. and HENIKOFF, J.G. "Performance Evaluation of Amino Acid Substitution Matrices," <i>PROTEINS: Structure, Function, and Genetics</i> , 1993, pp. 49-61, Vol. 17. | |
| /MH/ | R26 | HERRICK, C.A. and BOTTOMLY, K. "To Respond or Not to Respond: T Cells in Allergic Asthma," <i>Nat Rev Immunol</i> , May 2003, pp. 405-412, Vol. 3. | |

| | | | |
|--------------------|----------------|-----------------|------------|
| Examiner Signature | /Maher Haddad/ | Date Considered | 10/11/2007 |
|--------------------|----------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--------------------------------------------------------------------------------------------------------------------------------|---|--------------------------|-------------------|------------------------|---------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | Complete if Known | | | |
| | | Application Number | 10/565,741 | | |
| | | Filing Date | January 23, 2006 | | |
| | | First Named Inventor | Yolande Chvatchko | | |
| | | Group Art Unit | 1644 | | |
| | | Examiner Name | | | |
| Sheet | 4 | of | 6 | Attorney Docket Number | ARS-120 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| /MH/ | R27 | HIGGINS, D.G. <i>et al.</i> "Using CLUSTAL for Multiple Sequence Alignments," <i>Methods in Enzymology</i> , 1996, pp. 383-402, Vol. 266. | |
| | R28 | HRUBY, V.J. and BALSE, P.M. "Conformational and Topographical Considerations in Designing Agonist Peptidomimetics from Peptide Leads," <i>Current Medicinal Chemistry</i> , 2000, pp. 945-970, Vol. 7. | |
| | R29 | KARLIN, S. and ALTSCHUL, S.F. "Methods for assessing the statistical significance of molecular sequence features by using general scoring schemes," <i>Proc Natl Acad Sci USA</i> , March 1990, pp. 2264-2268, Vol. 87. | |
| | R30 | LEE, Y.-N. <i>et al.</i> "Identification of a Role for the Sialomucin CD164 in Myogenic Differentiation by Signal Sequence Trapping in Yeast," <i>Molecular and Cellular Biology</i> , November 2001, pp. 7696-7706, Vol. 21, No. 22. | |
| | R31 | LENHARD, T. <i>et al.</i> "A new set of versatile vectors for the heterologous expression of foreign genes using the baculovirus system," <i>Gene</i> , 1996, pp. 187-190, Vol. 169. | |
| | R32 | LUO, Y. and PRESTWICH, G. "Novel biomaterials for drug delivery," <i>Expert Opin. Ther. Patents</i> , 2001, pp. 1395-1410, Vol. 11, No. 9. | |
| | R33 | MALIK, F. <i>et al.</i> "Polyethylene Glycol (PEG)-modified Granulocyte-Macrophage Colony-stimulating Factor (GM-CSF) with Conserved Biological Activity," <i>Exp. Hematol.</i> , 1992, pp. 1028-1035, Vol. 20. | |
| | R34 | MARSHALL, S.A. <i>et al.</i> "Rational design and engineering of therapeutic proteins," <i>Drug Discov Today</i> , March 2003, pp. 212-221, Vol. 8, No. 5. | |
| | R35 | MATSUI, T. <i>et al.</i> "The Ratio of Splicing Variants of MGC-24/CD164, a Sialomucin, Correlates with the Metastatic Potential of Colorectal Carcinomas," <i>J. Biochem</i> , 2000, pp. 1103-1107, Vol. 127, No. 6. | |
| | R36 | MUIR, T.W. "Semisynthesis of Proteins by Expressed Protein Ligation," <i>Annu. Rev. Biochem.</i> , 2003, pp. 249-289, Vol. 72. | |
| | R37 | MURPHY, L.R. <i>et al.</i> "Simplified amino acid alphabets for protein fold recognition and implications for folding," <i>Protein Engineering</i> , 2000, pp. 149-152, Vol. 13, No. 3. | |
| ✓ | R38 | NICOLAU, C. <i>et al.</i> "Liposomes as Carriers for <i>In Vivo</i> Gene Transfer and Expression," <i>Methods in Enzymology</i> , 1987, pp. 157-176, Vol. 149. | |
| /MH/ | R39 | OHNO, T. <i>et al.</i> "Gene Therapy for Vascular Smooth Muscle Cell Proliferation After Arterial Injury," <i>Science</i> , August 5, 1994, pp. 781-784, Vol. 265. | |

| | | | |
|--------------------|----------------|-----------------|------------|
| Examiner Signature | /Maher Haddad/ | Date Considered | 10/11/2007 |
|--------------------|----------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

| | |
|------------------------|-------------------|
| Application Number | 10/565,741 |
| Filing Date | January 23, 2006 |
| First Named Inventor | Yolande Chvatchko |
| Group Art Unit | 1644 |
| Examiner Name | |
| Attorney Docket Number | ARS-120 |

Sheet

5

of

6

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|--------------------|-----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|
| /MH/ | R40 | PEARSON, W.R. and LIPMAN, D.J. "Improved tools for biological sequence comparison," <i>Proc Natl Acad Sci USA</i> , April 1988, pp. 2444-2448, Vol. 85. | |
| | R41 | PILLAI, O. and PANCHAGNULA, R. "Polymers in drug delivery," <i>Current Opinion in Chemical Biology</i> , 2001, pp. 447-451, Vol. 5. | |
| | R42 | ROGOV, S.I. and NEKRASOV, A.N. "A numerical measure of amino acid residues similarity based on the analysis of their surroundings in natural protein sequences," <i>Protein Engineering</i> , 2001, pp. 459-463, Vol. 14, No. 7. | |
| | R43 | SCHELLEKENS, H. "Bioequivalence and the Immunogenicity of Biopharmaceuticals," <i>Nat Rev Drug Discov</i> , June 2002, pp. 457-462, Vol. 1. | |
| | R44 | SMITH, G.E. <i>et al.</i> "Production of Human Beta Interferon in Insect Cells Infected with a Baculovirus Expression Vector," <i>Molecular and Cellular Biology</i> , December 1983, pp. 2156-2165, Vol. 3, No. 12. | |
| | R45 | TASCON, R.E. <i>et al.</i> "Vaccination against tuberculosis by DNA injection," <i>Nature Medicine</i> , August 1996, pp. 888-892, Vol. 2, No. 8. | |
| | R46 | TERPE, K. "Overview of tag protein fusions: from molecular and biochemical fundamentals to commercial systems," <i>Appl Microbiol Biotechnol</i> , 2003, pp. 523-533, Vol. 60. | |
| | R47 | THOMPSON, J.D. <i>et al.</i> "CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice," <i>Nucleic Acids Research</i> , 1994, pp. 4673-4680, Vol. 22, No. 22. | |
| | R48 | TUTUNCU, Z. <i>et al.</i> "Anti-TNF therapy for other inflammatory conditions," <i>Clin Exp Rheumatol</i> , 2002, pp. S146-S151, Vol. 20 (Suppl 28). | |
| | R49 | VASSEROT, A.P. <i>et al.</i> "Optimization of protein therapeutics by directed evolution," <i>Drug Discov Today</i> , February 2003, pp. 118-126, Vol. 8, No. 3. | |
| | R50 | VILLAIN, M. <i>et al.</i> "Covalent capture: a new tool for the purification of synthetic and recombinant polypeptides," <i>Chemistry and Biology</i> , 2001, pp. 673-679, Vol. 8. | |
| ✓ | R51 | VLASAK, R. <i>et al.</i> "Nucleotide sequence of cloned cDNA coding for honeybee prepromelittin," <i>Eur. J. Biochem</i> , 1983, pp. 123-126, Vol. 135. | |
| /MH/ | R52 | WATT, S.M. <i>et al.</i> "Functionally defined CD164 epitopes are expressed on CD34 ⁺ cells throughout ontogeny but display distinct distribution patterns in adult hematopoietic and nonhematopoietic tissues," <i>Blood</i> , May 15, 2000, pp. 3113-3124, Vol. 95, No. 10. | |

Examiner
Signature

/Maher Haddad/

Date
Considered

10/11/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--------------------------------------------------------------------------------------------------------------------------------|---|----|--------------------------|------------------------|---------|
| Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | Complete if Known | | |
| | | | Application Number | 10/565,741 | |
| | | | Filing Date | January 23, 2006 | |
| | | | First Named Inventor | Yolande Chvatchko | |
| | | | Group Art Unit | 1644 | |
| | | | Examiner Name | | |
| Sheet | 6 | of | 6 | Attorney Docket Number | ARS-120 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| /MH/ | R53 | WATT, S.M. and CHAN, J.Y. "CD164-A Novel Sialomucin On CD34 ⁺ Cells," <i>Leukemia and Lymphoma</i> , 2000, pp. 1-25, Vol. 37, Nos. 1-2. | |
| /MH/ | R54 | WILSON, I.A., <i>et al.</i> "The Structure of an Antigenic Determinant in a Protein," <i>Cell</i> , July 1984, pp. 767-778, Vol. 37. | |
| /MH/ | R55 | WONG, T.-K. <i>et al.</i> "Appearance of β -lactamase activity in animal cells upon liposome-mediated gene transfer," <i>Gene</i> , 1980, pp. 87-94, Vol. 10. | |
| /MH/ | R56 | ZANNETTINO, A.C.W. <i>et al.</i> "The Sialomucin CD164 (MGC-24v) Is an Adhesive Glycoprotein Expressed by Human Hematopoietic Progenitors and Bone Marrow Stromal Cells That Serves as a Potent Negative Regulator of Hematopoiesis," <i>Blood</i> , October 15, 1998, pp. 2613-2628, Vol. 92, No. 8. | |
| /MH/ | R57 | ZANNETTINO, A.C.W. "CD164," <i>J Biol Regul Homeostat Agents</i> , 2001, pp. 394-396, Vol. 15. | |

| | | | |
|--------------------|----------------|-----------------|------------|
| Examiner Signature | /Maher Haddad/ | Date Considered | 10/11/2007 |
|--------------------|----------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.